Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week

What: Novartis has acquired Excellergy for $2 billion.
Why: The deal is aimed at gaining access to a next-generation allergy treatment.
Signal: The acquisition is the second multi-billion dollar deal for Novartis in a week.
Target: The treatment is expected to work faster and more effectively than existing options.
Risk: The success of the treatment is still uncertain and subject to clinical trials.